Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding$1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.

Biotechnology

Health Care

Health Diagnostics

Alzeca Biosciences

Org chart

Teams

Scientific Advisory Team

Similar companies